Raptor Pharmaceutica (RPTP) 5.89 $RPTP
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GlobeNewswire - Thu Jul 28, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
GlobeNewswire - Fri Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIR to inhaled tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infections that were presented at the 39 European Cystic Fibrosis Conference in Basel, Switzerland.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) at European Cystic Fibrosis Conference
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:07PM CDT
PROCYSBI Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 5.89 (-0.03)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.89 (-0.03), EBIO: 3.97 (-0.40), PTCT: 5.97 (+0.20), PETX: 7.59 (+0.25), ARRY: 3.74 (-0.03)
Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 5.89 (-0.03)
Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 10:22AM CDT
Image source: Raptor Pharmaceuticals Corp. What: Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence . ...
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Launches QUINSAIR(TM) in Europe
GlobeNewswire - Mon Apr 11, 6:05AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR(TM) (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.
RPTP: 5.89 (-0.03)
Raptor's PROCYSBI(R) New Drug Submission Accepted by Health Canada with Priority Review
GlobeNewswire - Mon Mar 21, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.
RPTP: 5.89 (-0.03)
Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin
GlobeNewswire - Wed Mar 16, 6:30AM CDT
Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous Mycobacteria
RPTP: 5.89 (-0.03)
Is Raptor Pharmaceuticals Corp. Stock a Buy Right Now?
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 14, 12:10PM CDT
Image source: Pixabay. A phase 2 failure in the middle of a biotech meltdown has been tough on Raptor Pharmaceuticals ' stock. The shares have lost over 70% since their lofty peaks last June. While the stock might be as volatile as a...
RPTP: 5.89 (-0.03)
Why Raptor Pharmaceutical Corp. Plunged 13.1% in February
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 9:40AM CST
Image Source: Raptor Pharmaceuticals. What: Shares of Raptor Pharmaceuticals , a biopharmaceutical company that focuses on creating treatments for rare diseases, had a rough February, as the company's stock lost 13.1% of its value during the...
RPTP: 5.89 (-0.03), FBT: 100.26 (+1.85)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.89 (-0.03), TTNP: 4.96 (-0.08), MNKD: 0.99 (+0.02), TLOG: 0.23 (unch)
Biotech Sector Report; Potential Rebound for These Four Biotech Securities
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / MannKind Corporation (NASDAQ: MNKD), Fate Therapeutics Inc. (NASDAQ: FATE), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), and Zafgen Inc. (NASDAQ: ZFGN) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals.
ZFGN: 3.04 (+0.04), FATE: 2.07 (+0.09), RPTP: 5.89 (-0.03), MNKD: 0.99 (+0.02)
Four New Patents Issued, PROCYSBI(R) Granted Additional U.S. Orphan Exclusivity
GlobeNewswire - Mon Jan 25, 6:05AM CST
Five Patents for PROCYSBI Now Listed in FDA Orange Book
RPTP: 5.89 (-0.03)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 97.00 (+0.79), BMRN: 99.42 (+1.22), VYGR: 14.74 (+0.46), RPTP: 5.89 (-0.03), KNMD: (), SGMO: 6.33 (+0.17), BCLI: 2.55 (+0.04), CUR: 0.24 (unch)
Biotechnology Equities Scrutiny -- Advaxis, Raptor Pharma, Vanda Pharma, and Infinity Pharma
ACCESSWIRE - Thu Jan 14, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Park Lane Advisor has initiated coverage on the following equities: Advaxis Inc. (NASDAQ: ADXS), Raptor Pharmaceuticals Corporation (NASDAQ: RPTP), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Advaxis can be accessed at http://www.parklaneadvisor.com/ On Wednesday, January 13, 2016, the NASDAQ Composite ended at 4,526.06, down 3.41%, the Dow Jones Industrial Average declined 2.21%, to finish the day at 16,151.41, and the S&P 500 closed at 1,890.28, down 2.50%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
ADXS: 8.34 (+0.16), RPTP: 5.89 (-0.03), VNDA: 11.40 (-0.10), INFI: 1.68 (+0.06)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), ICPT: 173.03 (+6.13), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), LPTN: 1.95 (-0.05)
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
GlobeNewswire - Thu Jul 28, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR(TM) at the 39th European Cystic Fibrosis Conference
GlobeNewswire - Fri Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIR to inhaled tobramycin solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infections that were presented at the 39 European Cystic Fibrosis Conference in Basel, Switzerland.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Present Data on QUINSAIR(TM) at European Cystic Fibrosis Conference
GlobeNewswire - Tue Jun 07, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR(TM), an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:07PM CDT
PROCYSBI Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 5.89 (-0.03)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.89 (-0.03), EBIO: 3.97 (-0.40), PTCT: 5.97 (+0.20), PETX: 7.59 (+0.25), ARRY: 3.74 (-0.03)
Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 5.89 (-0.03)
Why Raptor Pharmaceuticals Corp. Stock Rose 25% in March
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 11, 10:22AM CDT
Image source: Raptor Pharmaceuticals Corp. What: Shares of Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), a biopharmaceutical focused on treating rare diseases, rose 25% last month, according to data from S&P Global Market Intelligence . ...
RPTP: 5.89 (-0.03)
Raptor Pharmaceutical Launches QUINSAIR(TM) in Europe
GlobeNewswire - Mon Apr 11, 6:05AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR(TM) (levofloxacin inhalation solution) in Germany and Denmark. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. The treatment is administered twice-daily, stored at room temperature and has a short administration time. Launches in additional EU countries and Canada are anticipated for QUINSAIR in 2016.
RPTP: 5.89 (-0.03)
Raptor's PROCYSBI(R) New Drug Submission Accepted by Health Canada with Priority Review
GlobeNewswire - Mon Mar 21, 3:05PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.
RPTP: 5.89 (-0.03)
Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin
GlobeNewswire - Wed Mar 16, 6:30AM CDT
Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous Mycobacteria
RPTP: 5.89 (-0.03)
Is Raptor Pharmaceuticals Corp. Stock a Buy Right Now?
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 14, 12:10PM CDT
Image source: Pixabay. A phase 2 failure in the middle of a biotech meltdown has been tough on Raptor Pharmaceuticals ' stock. The shares have lost over 70% since their lofty peaks last June. While the stock might be as volatile as a...
RPTP: 5.89 (-0.03)
Why Raptor Pharmaceutical Corp. Plunged 13.1% in February
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 9:40AM CST
Image Source: Raptor Pharmaceuticals. What: Shares of Raptor Pharmaceuticals , a biopharmaceutical company that focuses on creating treatments for rare diseases, had a rough February, as the company's stock lost 13.1% of its value during the...
RPTP: 5.89 (-0.03), FBT: 100.26 (+1.85)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.89 (-0.03), TTNP: 4.96 (-0.08), MNKD: 0.99 (+0.02), TLOG: 0.23 (unch)
Biotech Sector Report; Potential Rebound for These Four Biotech Securities
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / MannKind Corporation (NASDAQ: MNKD), Fate Therapeutics Inc. (NASDAQ: FATE), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), and Zafgen Inc. (NASDAQ: ZFGN) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals.
ZFGN: 3.04 (+0.04), FATE: 2.07 (+0.09), RPTP: 5.89 (-0.03), MNKD: 0.99 (+0.02)
Four New Patents Issued, PROCYSBI(R) Granted Additional U.S. Orphan Exclusivity
GlobeNewswire - Mon Jan 25, 6:05AM CST
Five Patents for PROCYSBI Now Listed in FDA Orange Book
RPTP: 5.89 (-0.03)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 97.00 (+0.79), BMRN: 99.42 (+1.22), VYGR: 14.74 (+0.46), RPTP: 5.89 (-0.03), KNMD: (), SGMO: 6.33 (+0.17), BCLI: 2.55 (+0.04), CUR: 0.24 (unch)
Biotechnology Equities Scrutiny -- Advaxis, Raptor Pharma, Vanda Pharma, and Infinity Pharma
ACCESSWIRE - Thu Jan 14, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 14, 2016 / Park Lane Advisor has initiated coverage on the following equities: Advaxis Inc. (NASDAQ: ADXS), Raptor Pharmaceuticals Corporation (NASDAQ: RPTP), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Advaxis can be accessed at http://www.parklaneadvisor.com/ On Wednesday, January 13, 2016, the NASDAQ Composite ended at 4,526.06, down 3.41%, the Dow Jones Industrial Average declined 2.21%, to finish the day at 16,151.41, and the S&P 500 closed at 1,890.28, down 2.50%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
ADXS: 8.34 (+0.16), RPTP: 5.89 (-0.03), VNDA: 11.40 (-0.10), INFI: 1.68 (+0.06)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.89 (-0.03), GALT: 1.64 (+0.07), ICPT: 173.03 (+6.13), RGLS: 3.57 (unch), ABBV: 66.23 (+1.51), LPTN: 1.95 (-0.05)
